Sector Expert: Jerry Isaacson

LifeSci Advisors , LifeSci Capital



Recent Quotes

"RNN's Archexin could generate $175M-$524M in peak annual revenues."

— Jerry Isaacson, LifeSci Capital (5/23/16)
more >

"IMUC will initiate a Phase 3 trial of ICT-107 based on the results of Phase 2."

— Jerry Isaacson, LifeSci Capital (4/2/15)
more >

"New results help define the potential for THLD's Phase 3 success."

— Jerry Isaacson, LifeSci Advisors (1/27/15)
more >

"DMPI's refractory GBM drug also has immediate opportunities in front-line GBM, a $1B opportunity."

— Jerry Isaacson, LifeSci Advisors (1/9/15)
more >

"Initial data from THLD's TH-302 with TBorD trial are encouraging."

— Jerry Isaacson, LifeSci Advisors (12/12/14)
more >

"THLD's partner Merck completed MAESTRO enrollment ahead of schedule."

— Jerry Isaacson, LifeSci Advisors (11/7/14)
more >

"We are initiating coverage on THLD."

— Jerry Isaacson, LifeSci Advisors (9/15/14)
more >

"DMPI announced FDA approval for an expanded dosing regimen in a Phase 1/2 trial evaluating VAL-083 in glioblastoma multiforme patients."

— Jerry Isaacson, LifeSci Advisors (8/21/14)
more >



Due to permission requirements, not all quotes are shown.